NCT04811378

HaemoCerTM Application in Breast Cancer Surgery

Randomised Controlled Trial: HaemoCerTM Versus no HaemoCerTM in Breast Cancer Surgery to Reduce Postoperative Drainage Output

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 136 (actual)
• Sponsor: Medical University of Vienna · Academic / Other
• Sex: Female
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

HaemoCer is a hemostatic agent to control bleedings during surgical procedures by accelerating natural hemostasis and is frequently applied during breast conserving surgery in women with breast cancer. There is however no adequate data available on the efficacy of HaemoCer regarding seroma formation or drainage output. The objective of this study is to investigate whether the intraoperative application of haemostatic powder (HaemoCer) in breast-conserving surgery in breast cancer patients reduces the postoperative drainage output and number of days until drain removal (number of hospitalization days).

Conditions

• Breast Neoplasm Female
• Mastectomy, Segmental

Interventions

Type	Name	Description
OTHER	HaemoCer	Randomized application of 3g haemostatic powder (HaemoCer) in the wound site during breast-conserving surgery.

Timeline

• Start date: 2017-10-05
• Primary completion: 2021-03-01
• Completion: 2021-03-01
• First posted: 2021-03-23
• Last updated: 2021-09-13

Locations

1 site across 1 country: Austria